Project Grant HT94252510158
Award Date
3/15/25
Completion Date
3/14/27
Dollars Obligated
$260K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14203, USA
Similar Awards
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis.
This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions...
The U.S. Department of Defense's Defense Health Agency awarded Health Research, Inc. a $1,545,300 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING MYCAF-DRIVEN CASTRATION-RESISTANT PROSTATE TUMOR GROWTH." The award, which has a performance period of May 1, 2024 to April 30, 2027, will enable Health Research, Inc.'s Roswell Park Division to perform biomedical research and provide scientific services to advance...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The federal Project Grant award, issued by the Defense Health Agency, provides $282,000.00 in funding to The Institute For Cancer Research to support the research project "EXPLORING THE ROLE OF MUL1 IN PROSTATE TUMORIGENESIS" over the period of May 1, 2025 to April 30, 2027. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives aimed at improving health outcomes for military service members,...
This $1,839,317 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) aims to evaluate the interrelated roles of environmental exposures and multi-omic factors on high-risk prostate cancer among men of African ancestry in Africa. The prime awardee, the University of Illinois, will lead the "PCAPH AFRICA1K" initiative to improve prostate cancer outcomes in Africa through precision health approaches. As a...
The Department of Defense's Defense Health Agency awarded a $1,460,695 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. for the project "Development and Validation of an Epigenomic Landscape and Novel Immunotherapy in Prostate Cancer Disparities". The award period is from September 1, 2025 to August 31, 2028. The purpose of this grant is to support research...
The U.S. Defense Health Agency awarded a $468,672 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Georgia College & State University and its partners Mayo Clinic and The University of Texas MD Anderson Cancer Center. This grant, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium", aims to conduct research examining health-seeking behaviors, decision-making, psychosocial effects, and coping mechanisms...
This $1,301,250.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Health Research, Inc. The grant will fund research to inhibit myeloid-derived suppressor cell (MDSC) biogenesis in order to augment the efficacy of immunotherapy in treating triple-negative breast cancer. The project will be carried out at Health Research, Inc.'s Roswell Park Division located in Buffalo, NY and is scheduled to run from March 1,...